Likmez (Metronidazole Oral)
Brand Names: Likmez
Methodology & AI Transparency ⓘ
Likmez (Metronidazole Oral) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Likmez and registered by Kesin Pharma Corporation, this nitroimidazole antimicrobial product delivers active moiety Metronidazole Oral (cross-referenced at /meds/metronidazole-oral) (100 mg/mL Suspension; 250mg Tablet).
- 2 Real-world patient consensus: Likmez links directly to generic Metronidazole Oral (/meds/metronidazole-oral) under FDA SPL 2024-12-30 (NDC 81033-066).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $195.25 cash mean against $517.41 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Likmez (Metronidazole Oral) include nausea (12.6%), headache (11.2%), diarrhea (9.9%).
Ask our AI Specialists anything about Likmez (Metronidazole Oral)
Likmez (Metronidazole Oral) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Likmez and registered by Kesin Pharma Corporation, this nitroimidazole antimicrobial product delivers active moiety Metronidazole Oral (cross-referenced at /meds/metronidazole-oral) (100 mg/mL Suspension; 250mg Tablet). Federal labeling (2024-12-30, RxCUI 2667648) defines its therapeutic scope: 1 Indications and usage likmez: is a nitroimidazole antimicrobial indicated for Trichomoniasis in adults ( 1.1 ).
Inside Likmez, Metronidazole Oral mediates nitroimidazole antimicrobial pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (100 mg/mL Suspension; 250mg Tablet). Commercial labeling registered by Kesin Pharma Corporation (SPL 2024-12-30, RxNorm 2667648) pairs standardized excipient stability with federal price transparency metrics ($2.5938/unit NADAC; $517.41 retail average).
With Approximately 3–16 hours terminal plasma half-life for Likmez (Metronidazole Oral) residence kinetics and Estimated 56%–68% oral systemic absorption for Likmez (Metronidazole Oral) bioavailability, Likmez (Metronidazole Oral) undergoes phase i/ii hepatic conjugation of likmez (metronidazole oral) coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for likmez (metronidazole oral).
Standard adult regimens span 100 mg/mL Suspension, 250mg Tablet, 0.75% Vaginal Gel, 0.75% Tube of Cream, 0.75% Tube of Gel. Prescribers screen specifically against known hypersensitivity to metronidazole oral or structurally related nitroimidazole antimicrobial compounds; concomitant contra-labeled cyp/transporter therapies during active likmez (metronidazole oral) administration, while community micro-logs most frequently note nausea (12.6% of reports), headache (11.2% of reports), diarrhea (9.9% of reports).
Co-administering Likmez (Metronidazole Oral) with coumarin anticoagulants can shift prothrombin INR values and heighten hemorrhage risk.
Additive central nervous system sedation and psychomotor slowing can occur when Likmez (Metronidazole Oral) is paired with sedatives or ethanol.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Metronidazole Oral or structurally related nitroimidazole antimicrobial compounds
- Concomitant contra-labeled CYP/transporter therapies during active Likmez (Metronidazole Oral) administration
Logged Side-Effect Incidence (15 Reports)
Likmez (Metronidazole Oral) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Likmez (Metronidazole Oral))
Human clinical trial evidence for Likmez (Metronidazole Oral) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Likmez (Metronidazole Oral) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.5938/unit (~$77.81/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $517.41 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $195.25 / mo | View logs ↓ |
Likmez (Metronidazole Oral) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Likmez (Metronidazole Oral) RxNorm Concept ID | 2667648 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.5938 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $517.41 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $195.25 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Likmez (Metronidazole Oral) Patient Community, Cohort Filters & Dosage Logs
Deterministic Likmez (Metronidazole Oral) reference combining NIH RxNorm (2667648), Medicaid NADAC ($2.5938/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Likmez (Metronidazole Oral) community threads and patient logs by age, biological sex, dosage, and treatment duration.